MEC
MCID: MCP006
MIFTS: 50

Mucoepidermoid Carcinoma (MEC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Mucoepidermoid Carcinoma

MalaCards integrated aliases for Mucoepidermoid Carcinoma:

Name: Mucoepidermoid Carcinoma 12 52 15 71
Carcinoma, Mucoepidermoid 43
Carcinoma Mucoepidermoid 54
C3772 52
Mec 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4531
MeSH 43 D018277
NCIt 49 C3772
SNOMED-CT 67 4079000
UMLS 71 C0206694

Summaries for Mucoepidermoid Carcinoma

NIH Rare Diseases : 52 Mucoepidermoid carcinoma is a type of cancer of the salivary glands . Salivary gland cancer is diagnosed in 2-3 individuals per 100,000 people each year, and 30-35% of these are mucoepidermoid carcinomas. Mucoepidermoid carcinoma develops when a cell randomly acquires changes (mutations ) in genes that regulate how the cell divides such that it begins to grow quickly, forming a cluster of cells (a mass or lump). The earliest signs of a mucoepidermoid carcinoma may include a lump in the face, neck, or mouth; numbness, weakness, or pain in part of the face; or difficulty swallowing. Treatment often begins with surgery to remove the entire tumor . In some cases, radiation therapy and/or chemotherapy may be used after surgery to ensure that no cancer cells remain in the body.

MalaCards based summary : Mucoepidermoid Carcinoma, also known as carcinoma, mucoepidermoid, is related to lacrimal gland mucoepidermoid carcinoma and thyroid gland mucoepidermoid carcinoma. An important gene associated with Mucoepidermoid Carcinoma is LINC00473 (Long Intergenic Non-Protein Coding RNA 473), and among its related pathways/superpathways is Keratinization. The drugs Cevimeline and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, lung and thyroid.

Disease Ontology : 12 A salivary gland carcinoma that is characterized by squamous cells, mucus-secreting cells, and intermediate cells.

Wikipedia : 74 Mucoepidermoid carcinoma is the most common type of minor salivary gland malignancy in adults.... more...

Related Diseases for Mucoepidermoid Carcinoma

Diseases related to Mucoepidermoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 579)
# Related Disease Score Top Affiliating Genes
1 lacrimal gland mucoepidermoid carcinoma 34.9 MAML2 CRTC1
2 thyroid gland mucoepidermoid carcinoma 34.8 TG CALCA
3 breast mucoepidermoid carcinoma 34.8 MUC5AC MAML2 CRTC1
4 laryngeal mucoepidermoid carcinoma 34.6 KRT14 CEACAM5
5 lung mucoepidermoid carcinoma 34.5 MUC5AC MAML2
6 cutaneous mucoepidermoid carcinoma 34.5 MAML2 KRT7 CRTC1 CEACAM5
7 bile duct mucoepidermoid carcinoma 34.0 MUC5AC MUC4 MUC1 MAML2 KRT7 CRTC1
8 ceruminous adenocarcinoma 33.1 KRT7 KRT14
9 salivary gland carcinoma 33.0 SERPINA3 MAML2 KRT7 EGFR CRTC3 CRTC1
10 adenoma 31.5 TG MUC5AC MUC1 KRT7 CHGA
11 pleomorphic adenoma 31.5 TP63 S100A1 MUC1 MAML2 KRT7 KRT14
12 pancreatic adenosquamous carcinoma 31.4 MAML2 CRTC3 CRTC1
13 pleomorphic adenoma carcinoma 31.4 MAML2 CRTC3 CRTC1
14 warthin tumor 31.4 MAML2 KRT7 CRTC3 CRTC1 CEACAM5
15 adenocarcinoma 31.3 MUC4 MUC1 KRT7 EGFR CEACAM5
16 intrahepatic cholangiocarcinoma 31.2 MUC5AC MUC4 MUC1 KRT7 EGFR
17 myoepithelial carcinoma 31.1 MUC1 KRT7 KRT14
18 oncocytoma 31.1 S100A1 MUC1 KRT7 KRT14
19 necrotizing sialometaplasia 31.0 TP63 MAML2 KRT7
20 in situ carcinoma 31.0 SERPINA3 MUC1 KRT14 EGFR
21 adenoid cystic carcinoma 31.0 TP63 SERPINA3 S100A1 MUC1 KRT7 KRT14
22 epithelial-myoepithelial carcinoma 31.0 MAML2 KRT7 KRT14
23 polymorphous low-grade adenocarcinoma 31.0 TP63 S100A1 MUC1
24 schneiderian carcinoma 30.9 MAML2 CRTC1
25 papillary carcinoma 30.9 TG S100A1 MUC1 KRT7 CHGA CALCA
26 cervical adenosquamous carcinoma 30.9 MAML2 EGFR CRTC1
27 acinar cell carcinoma 30.8 SERPINA3 KRT7 CHGA
28 cholangiocarcinoma 30.8 MUC5AC MUC4 MUC1 KRT7 EGFR CEACAM5
29 thymoma 30.8 TP63 TG MUC1 KRT7 EGFR
30 esophageal adenosquamous carcinoma 30.8 KRT7 KRT14 CEACAM5
31 pleomorphic carcinoma 30.7 KRT7 KRT14 EGFR
32 carcinosarcoma 30.7 S100A1 MUC1 KRT7 EGFR CEACAM5
33 bronchiolo-alveolar adenocarcinoma 30.7 MUC5AC MUC4 KRT7 EGFR CEACAM5
34 myoepithelioma 30.6 TP63 S100A1 MUC1 KRT14
35 villous adenoma 30.6 MUC5AC MUC1 CEACAM5
36 papillary adenocarcinoma 30.6 MUC1 KRT7 CEACAM5
37 thymic carcinoma 30.5 TP63 TG MUC1 KRT7 EGFR CEACAM5
38 mammary paget's disease 30.5 MUC1 KRT7 KRT14 EGFR CALCA
39 mature teratoma 30.5 TG KRT7 CEACAM5
40 mucinous adenocarcinoma 30.5 MUC5AC MUC1 KRT7 EGFR CEACAM5
41 papilloma 30.5 TP63 KRT7 KRT14 KRT13 IVL EGFR
42 hidradenoma 30.5 MUC1 MAML2 KRT7 CRTC3 CRTC1 CEACAM5
43 spindle cell sarcoma 30.5 SERPINA3 MUC1 KRT7
44 lung benign neoplasm 30.5 KRT7 EGFR CHGA
45 cystic teratoma 30.5 MUC5AC KRT7 CEACAM5
46 syringocystadenoma papilliferum 30.5 SERPINA3 MUC1
47 apocrine adenocarcinoma 30.4 SERPINA3 MUC1 KRT7 EGFR
48 signet ring cell adenocarcinoma 30.4 MUC5AC MUC1 KRT7 CHGA CEACAM5
49 clear cell hidradenoma 30.4 MAML2 KRT7 CRTC3 CRTC1 CEACAM5
50 neurilemmoma 30.4 SERPINA3 S100A1 MUC1

Graphical network of the top 20 diseases related to Mucoepidermoid Carcinoma:



Diseases related to Mucoepidermoid Carcinoma

Symptoms & Phenotypes for Mucoepidermoid Carcinoma

Drugs & Therapeutics for Mucoepidermoid Carcinoma

Drugs for Mucoepidermoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
2
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
3
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
5
Promethazine Approved, Investigational Phase 3 60-87-7 4927
6
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
7
Histamine Approved, Investigational Phase 3 51-45-6 774
8
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
9
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Neurotransmitter Agents Phase 3
13 Liver Extracts Phase 3
14 Cola Phase 3
15 Muscarinic Agonists Phase 3
16 Cholinergic Agents Phase 3
17 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
18 Hormone Antagonists Phase 2, Phase 3
19 Antifungal Agents Phase 2, Phase 3
20 Antidepressive Agents Phase 3
21 Hypnotics and Sedatives Phase 3
22 Histamine Antagonists Phase 3
23 Psychotropic Drugs Phase 3
24
Histamine Phosphate Phase 3 51-74-1 65513
25 Antidepressive Agents, Tricyclic Phase 3
26 Central Nervous System Stimulants Phase 3
27 Contraceptives, Oral Phase 3
28 Antineoplastic Agents, Hormonal Phase 3
29 Contraceptive Agents Phase 3
30
Megestrol Phase 3 3562-63-8 19090 3080587
31 Anesthetics Phase 3
32 Narcotics Phase 3
33 Analgesics Phase 3
34 Analgesics, Opioid Phase 3
35 Anesthetics, General Phase 3
36 Anesthetics, Intravenous Phase 3
37
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
38
Indinavir Approved Phase 2 150378-17-9 5362440
39
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
40
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
41
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
42
Lenograstim Approved, Investigational Phase 2 135968-09-1
43
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
44
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
45
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
48
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
2 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
3 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
4 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
6 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
7 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
9 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
10 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
12 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
13 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
14 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
15 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
16 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
17 Gemcitabine for Advanced Salivary Cancer: A Phase II Study Completed NCT00003744 Phase 2 gemcitabine
18 A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
19 PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES Completed NCT00002632 Phase 2 paclitaxel
20 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
21 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
22 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
23 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
24 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
25 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
26 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
27 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
28 Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung Completed NCT00021333 Phase 2 cisplatin;paclitaxel
29 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Recruiting NCT03602079 Phase 1, Phase 2 A166
30 A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Recruiting NCT01220583 Phase 2 cisplatin
31 Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma Terminated NCT00126607 Phase 2
32 Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin
33 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
34 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
35 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
36 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
37 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
38 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
39 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
40 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
41 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
42 Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
43 A Phase I Study of NX 211 in Combination With Cisplatin Given as an IV Infusion Days 1, 2, and 3 Every 3 Weeks in Patients With Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
44 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
45 A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol Completed NCT00004065 Phase 1 tanespimycin
46 VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER Completed NCT00019110 Phase 1
47 A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System Completed NCT00010023 Phase 1 capecitabine;cisplatin
48 PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES AND VARYING DEGREES OF LIVER DYSFUNCTION Completed NCT00002901 Phase 1 docetaxel
49 Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies Completed NCT00045006 Phase 1 vorinostat
50 A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride

Search NIH Clinical Center for Mucoepidermoid Carcinoma

Cochrane evidence based reviews: carcinoma, mucoepidermoid

Genetic Tests for Mucoepidermoid Carcinoma

Anatomical Context for Mucoepidermoid Carcinoma

MalaCards organs/tissues related to Mucoepidermoid Carcinoma:

40
Salivary Gland, Lung, Thyroid, Breast, Liver, Tongue, Trachea

Publications for Mucoepidermoid Carcinoma

Articles related to Mucoepidermoid Carcinoma:

(show top 50) (show all 2606)
# Title Authors PMID Year
1
Primary mucoepidermoid carcinoma of the skin expressing p63. 54 61
19786853 2010
2
Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. 54 61
19531414 2009
3
Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: possible significance of CRTC1-MAML2 oncogene. 61 54
19185385 2009
4
Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. 61 54
18992960 2009
5
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. 54 61
18542074 2008
6
Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy. 61 54
18202792 2008
7
Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. 54 61
17391298 2007
8
Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature. 61 54
16996786 2006
9
Clinicopathologic and immunohistochemical study of intraoral mucoepidermoid carcinoma. 61 54
16564385 2006
10
Clinical prognostic factors in malignant parotid gland tumors. 54 61
16274796 2005
11
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. 54 61
16009452 2005
12
Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model. 61 54
15880136 2005
13
MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications. 61 54
15958852 2005
14
PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumours. 54 61
15308260 2004
15
MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. 54 61
15054739 2004
16
Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex. 54 61
12021924 2002
17
Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland. 61 54
11598171 2001
18
High tumor grade in salivary gland mucoepidermoid carcinomas and loss of expression of transforming growth factor beta receptor type II. 54 61
11405868 2001
19
Application of immunohistochemistry to the diagnosis of salivary gland tumors. 54 61
10981871 2000
20
Proliferating cell nuclear antigen expression in mucoepidermoid carcinoma of salivary glands. 54 61
10810331 2000
21
Immunohistochemical study of basaloid squamous cell carcinoma, adenoid cystic and mucoepidermoid carcinoma in the upper aerodigestive tract. 54 61
10810423 2000
22
Fine needle aspiration biopsy of salivary gland lesions. A reappraisal of pitfalls and problems. 61 54
9684573 1998
23
A new view of the so-called adenoma malignum of the uterine cervix. 61 54
9565340 1998
24
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in human benign and malignant epithelial lesions of the parotid gland. 54 61
9192550 1997
25
[Expression of proliferating cell nuclear antigen and tumor suppressor gene P53 in mucoepidermoid carcinoma of salivary glands]. 61 54
9592256 1996
26
Radioimmunological and immunohistochemical study of carcinoembryonic antigen in pleomorphic adenoma and mucoepidermoid carcinoma of the salivary glands. 54 61
8705787 1996
27
Primary mucoepidermoid carcinoma of the thyroid gland: a report of six cases and a review of the literature of a follicular epithelial-derived tumor. 61 54
7557943 1995
28
Staging of salivary gland neoplasms: role of histopathologic and molecular factors. 54 61
7977956 1994
29
High correlation with survival of proliferating cell nuclear antigen expression in mucoepidermoid carcinoma of the parotid gland. 54 61
7936679 1994
30
Mucoepidermoid carcinoma of the salivary glands: immunohistochemical distribution of intermediate filament proteins, involucrin and secretory proteins. 61 54
1377895 1992
31
Immunoprofile of mucoepidermoid carcinomas of minor salivary glands. 54 61
1706081 1991
32
Carcinosarcoma of the parotid gland with mucoepidermoid carcinoma component. 61
32550959 2020
33
Retrospective Study of Buccal Mucosal Salivary Neoplasms. 61
32506376 2020
34
Synthetic tracheal grafts seeded with bone marrow cells fail to generate functional tracheae: First long-term follow-up study. 61
31859073 2020
35
Primary Malignant Epithelial Tumors of the Lacrimal Drainage System: A Major Review. 61
32506982 2020
36
Expression Levels of SIX1, ME2 and AP2M1 in Adenoid Cystic Carcinoma and Mucoepidermoid Carcinoma. 61
32564485 2020
37
Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. 61
32519264 2020
38
Fine-Needle Aspiration Cytology Is an Effective Diagnostic Tool in Paediatric Patients with Mucoepidermoid Carcinoma as Secondary Neoplasm. 61
32526741 2020
39
The role of elective neck dissection in high-grade parotid malignancy: A hospital-based cohort study. 61
31468551 2020
40
Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma. 61
32129900 2020
41
Salivary-Like Tumors of the Thyroid: A Comprehensive Review of Three Rare Carcinomas. 61
32562215 2020
42
Metastatic Biphasic Primitive Tumor in the Mandible of a Child. 61
32542629 2020
43
Cytologic grading of primary malignant salivary gland tumors: A blinded review by an international panel. 61
32267606 2020
44
Bronchoscopic intervention for a patient with bronchial mucoepidermoid carcinoma. 61
32265422 2020
45
Mucoepidermoid Carcinoma. An Update and Review of the Literature. 61
32565266 2020
46
Prevalence of mucoepidermoid carcinoma among intraoral minor salivary gland tumors: a systematic review and meta-analysis. 61
32531838 2020
47
Cetuximab monotherapy for relapsing high-grade mucoepidermoid carcinoma: A case report and review of the literature. 61
32518035 2020
48
Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study. 61
31954088 2020
49
Treatment outcomes of patients with tracheobronchial mucoepidermoid carcinoma compared with those with adenoid cystic carcinoma. 61
32418755 2020
50
Clinical outcomes and the role of bronchoscopic intervention in patients with primary pulmonary salivary gland-type tumors. 61
32512274 2020

Variations for Mucoepidermoid Carcinoma

Cosmic variations for Mucoepidermoid Carcinoma:

9 (show top 50) (show all 451)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM135127924 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 12
2 COSM105721467 salivary gland,mouth floor,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 11:534288-534288 12
3 COSM97921670 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 12
4 COSM133255277 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.117A>C p.K39N 9:99129081-99129081 12
5 COSM97906020 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 12
6 COSM143041461 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 9
7 COSM84855029 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 9
8 COSM99625361 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 9
9 COSM88223810 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 9
10 COSM87905712 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 9
11 COSM88218639 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 9
12 COSM87961733 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 9
13 COSM88043721 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.550G>C p.D184H 17:7675062-7675062 9
14 COSM87933369 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 9
15 COSM88075150 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.483C>T p.A161= 17:7675129-7675129 9
16 COSM87897745 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 9
17 COSM87912247 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 9
18 COSM87901886 TP53 salivary gland,minor,carcinoma,NS c.994-1G>A p.? 17:7670716-7670716 9
19 COSM88420642 THRA salivary gland,mouth floor,carcinoma,NS c.1162C>T p.R388W 17:40093071-40093071 9
20 COSM96852092 TENT5C salivary gland,minor,carcinoma,NS c.833T>A p.F278Y 1:117623701-117623701 9
21 COSM89651491 SMARCA4 salivary gland,minor,carcinoma,NS c.2372C>T p.A791V 19:11013046-11013046 9
22 COSM91381776 SMAD4 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.993G>A p.M331I 18:51065460-51065460 9
23 COSM87293136 SLC26A2 salivary gland,mouth floor,carcinoma,NS c.1474C>T p.R492W 5:149981067-149981067 9
24 COSM89628192 SF3B1 salivary gland,minor,carcinoma,NS c.3254C>T p.A1085V 2:197397997-197397997 9
25 COSM103044749 SETD2 salivary gland,minor,carcinoma,NS c.6379C>T p.Q2127* 3:47057405-47057405 9
26 COSM84139086 SDHA salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.724G>A p.G242R 5:228287-228287 9
27 COSM87217226 RUNX1 salivary gland,minor,carcinoma,NS c.958C>T p.R320* 21:34799310-34799310 9
28 COSM88241411 RPTOR salivary gland,minor,carcinoma,NS c.734C>T p.A245V 17:80754089-80754089 9
29 COSM85226318 RNF38 salivary gland,mouth floor,carcinoma,NS c.623A>G p.H208R 9:36357890-36357890 9
30 COSM97325050 RIT1 salivary gland,mouth floor,carcinoma,NS c.286C>G p.Q96E 1:155904733-155904733 9
31 COSM86829907 RARA salivary gland,minor,carcinoma,NS c.691C>G p.L231V 17:40352391-40352391 9
32 COSM146439398 PTPN11 salivary gland,minor,carcinoma,NS c.1517C>T p.S506L 12:112489081-112489081 9
33 COSM96879738 PTEN salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.760A>G p.K254E 10:87957978-87957978 9
34 COSM91776528 PPP2R1A salivary gland,mouth floor,carcinoma,NS c.548G>A p.R183Q 19:52212730-52212730 9
35 COSM96441053 PIK3CG salivary gland,minor,carcinoma,NS c.2951C>A p.P984Q 7:106886213-106886213 9
36 COSM87132308 PIK3CA salivary gland,minor,carcinoma,NS c.1633G>A p.E545K 3:179218303-179218303 9
37 COSM87138027 PIK3CA salivary gland,minor,carcinoma,NS c.3012G>A p.M1004I 3:179234169-179234169 9
38 COSM87132826 PIK3CA salivary gland,minor,carcinoma,NS c.1258T>C p.C420R 3:179210192-179210192 9
39 COSM87132245 PIK3CA salivary gland,mouth floor,carcinoma,NS c.3140A>G p.H1047R 3:179234297-179234297 9
40 COSM101277011 PBRM1 salivary gland,minor,carcinoma,NS c.2284G>C p.D762H 3:52609596-52609596 9
41 COSM84166347 NR1D1 salivary gland,mouth floor,carcinoma,NS c.*12G>A p.? 17:40093071-40093071 9
42 COSM87686111 NOTCH1 salivary gland,minor,carcinoma,NS c.403+1G>C p.? 9:136523716-136523716 9
43 COSM87645161 NOTCH1 salivary gland,minor,carcinoma,NS c.7400C>A p.S2467* 9:136496339-136496339 9
44 COSM87655472 NOTCH1 salivary gland,minor,carcinoma,NS c.1367G>A p.C456Y 9:136517826-136517826 9
45 COSM87673614 NOTCH1 salivary gland,minor,carcinoma,NS c.973A>G p.N325D 9:136518717-136518717 9
46 COSM87642161 NOTCH1 salivary gland,minor,carcinoma,NS c.5101G>C p.A1701P 9:136503248-136503248 9
47 COSM93664740 NF1 salivary gland,minor,carcinoma,NS c.3449C>G p.S1150* 17:31232834-31232834 9
48 COSM85374504 MELK salivary gland,mouth floor,carcinoma,NS c.817T>C p.W273R 9:36633183-36633183 9
49 COSM95014362 MAX salivary gland,minor,carcinoma,NS c.295+1G>A p.? 14:65077912-65077912 9
50 COSM106071509 MAP2K4 salivary gland,minor,carcinoma,NS c.584C>G p.S195W 17:12107827-12107827 9

Expression for Mucoepidermoid Carcinoma

Search GEO for disease gene expression data for Mucoepidermoid Carcinoma.

Pathways for Mucoepidermoid Carcinoma

Pathways related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.38 KRT7 KRT14 KRT13 IVL

GO Terms for Mucoepidermoid Carcinoma

Cellular components related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 TG SERPINA3 MUC5AC MUC4 MUC1 EGFR
2 extracellular exosome GO:0070062 9.61 SERPINA3 MUC5AC MUC4 MUC1 KRT7 KRT14
3 keratin filament GO:0045095 9.43 KRT7 KRT14 KRT13
4 extracellular region GO:0005576 9.32 TG SERPINA3 S100A1 MUC5AC MUC4 MUC1

Biological processes related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 O-glycan processing GO:0016266 9.33 MUC1 MUC4 MUC5AC
2 maintenance of gastrointestinal epithelium GO:0030277 9.32 MUC4 SERPINA3
3 positive regulation of keratinocyte proliferation GO:0010838 9.26 CDH3 TP63
4 cornification GO:0070268 9.26 IVL KRT13 KRT14 KRT7
5 keratinization GO:0031424 9.02 CDH3 IVL KRT13 KRT14 KRT7

Molecular functions related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cAMP response element binding protein binding GO:0008140 8.62 CRTC3 CRTC1

Sources for Mucoepidermoid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....